Clorox's (CLX) IGNITE Strategy to Evolve Portfolio Bodes Well
https://www.zacks.com/stock/news/2245096/clorox-s-clx-ignite-strategy-to-evolve-portfolio-bodes-well?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2245096
Mar 22, 2024 - Clorox (CLX) benefits from pricing actions and cost-saving initiatives. The company is on track to streamline its operating model to improve efficiency.
0
B&G Foods' (BGS) Innovation Pipeline Bodes Well Amid High Costs
https://www.zacks.com/stock/news/2244299/b-g-foods-bgs-innovation-pipeline-bodes-well-amid-high-costs?cid=CS-ZC-FT-analyst_blog|rank_focused-2244299
Mar 21, 2024 - B&G Foods (BGS) bolsters its product range with innovative seasoning blends and streamlines its portfolio for higher profitability despite facing challenges from increased SG&A expenses.
0
Accenture (ACN) to Post Q2 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2242259/accenture-acn-to-post-q2-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2242259
Mar 18, 2024 - Accenture's (ACN) second-quarter fiscal 2024 revenues and earnings are expected to have declined from the year-ago levels.
0
Is Post Holdings (POST) Stock Undervalued Right Now?
https://www.zacks.com/stock/news/2242105/is-post-holdings-post-stock-undervalued-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2242105
Mar 18, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
0
Are Consumer Staples Stocks Lagging Freshpet (FRPT) This Year?
https://www.zacks.com/stock/news/2242143/are-consumer-staples-stocks-lagging-freshpet-frpt-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2242143
Mar 18, 2024 - Here is how Freshpet (FRPT) and Post Holdings (POST) have performed compared to their sector so far this year.
0
StoneCo (STNE) to Post Q4 Earnings: What's in the Offing?
https://www.zacks.com/stock/news/2241559/stoneco-stne-to-post-q4-earnings-what-s-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-2241559
Mar 15, 2024 - StoneCo's (STNE) fourth-quarter 2023 performance will likely reflect strength in its financial services and software business.
0
H World Group (HTHT) to Post Q4 Earnings: What's in Store?
https://www.zacks.com/stock/news/2241487/h-world-group-htht-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2241487
Mar 15, 2024 - H World Group's (HTHT) fourth-quarter 2023 top line is likely to benefit from the sustained recovery in both leisure and business travel demand.
0
Philip Morris (PM) Advances Smoke-Free Evolution With New Launch
https://www.zacks.com/stock/news/2240745/philip-morris-pm-advances-smoke-free-evolution-with-new-launch?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2240745
Mar 14, 2024 - Philip Morris (PM) unveils the IQOS ILUMA i to continue offering enhanced alternatives to consumers. Philip Morris is well-placed to become a majority smoke-free company.
0
Deutsche Post: Why I Now Rate It A Hold Given Recent Performance
https://seekingalpha.com/article/4678082-deutsche-post-why-i-now-rate-it-a-hold-given-recent-performance?source=feed_all_articles
Mar 13, 2024 - Deutsche Post faces EBIT growth challenges due to economic uncertainty and shipping rates, prompting a downgrade from Buy to Hold. Read an analysis here.
0
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
https://www.zacks.com/stock/news/2240235/lexicon-lxrx-dips-on-post-hoc-analysis-data-on-sotagliflozin?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240235
Mar 13, 2024 - New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
0